Introduction The extraordinary feat of proving the effectiveness of oral pre‐exposure
prophylaxis (PrEP) in clinical trials in different populations in a variety of settings may prove …

Background In this article, we present recent evidence from studies focused on the
implementation, effectiveness and cost‐effectiveness of pre‐exposure prophylaxis (PrEP) for …

Pre‐exposure prophylaxis (PrEP) has been and continues to be an intervention that causes
controversy and debate between stakeholders involved in providing or advocating for it, and …

What do we know about the cost–effectiveness of HIV preexpos... : Current Opinion in HIV and
AIDS What do we know about the cost–effectiveness of HIV preexposure prophylaxis, and is it …

Future cost effectiveness studies should consider PrEP implementation issues (uptake in
high-risk versus low-risk groups, duration on PrEP, adherence), budget impact, and the role …

HIV prevention programs should determine strategies to identify those at substantial risk for
HIV infection, formulate and deliver PrEP in combination with interventions that target social …

More than a decade after the first efficacy evidence for oral HIV pre-exposure prophylaxis
(PrEP) was reported, PrEP uptake globally has been inadequate and global HIV prevention …

Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first
approved by the US Food and Drug Administration in 2012. Despite correlations of …

Abstract Purpose of Review The aim of this study is to summarise the recent evidence from
high-income settings about providers' ability to deliver on the UNAIDS goal of at least three …

Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years
where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling …